Companies: 10,795·Total market cap: $144.5T
Abbott Laboratories

Abbott Laboratories

ABTNYSEHealthcare● Active
$91.07
+$0.29(+0.32%)
Market Cap$158.6B
P/E Ratio
52W High$139.06
52W Low$81.97
Overview

Abbott Laboratories (ABT) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

abt · stock forecast · 41 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 41 Wall Street analysts in the past 3 months

SellBuy

Buy

41 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
31
Hold
10
Sell
0
Strong Sell
0
Total: 41 · Buy rate: 75.6%

12-Month Price Target

High

$152

Consensus

$127

+40.0% upside

Low

$92.00

Median: $125 · Last Close: $91.07

The Abbott Laboratories (ABT) analyst consensus is Buy, based on ratings from 41 Wall Street analysts over the past 3 months. The average 12-month ABT price target is $127.46, representing +40.0% upside from the current price of $91.07.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $127 (40.0%)

Consensus Target

$127.46

40.0% upside

High Target

$152

66.9%

Low Target

$92

1.0%

Current Price

$91.07

as of today

Based on analyst price targets, the ABT stock price prediction for the next 12 months ranges from $92 to $152. The consensus ABT price forecast of $127.46 implies 40.0% upside from the current price of $91.07.

Short-Term Price Prediction

Bear

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$92.631.71%

1-day model range: $92.24–$93.01. Peak: $93.01 (+1.71%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$89-2.6%
2028$87-4.2%
2029$86-5.2%
2030$86-5.9%
2031-6.3%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

43%0%57%
6Buy
0Neutral
8Sell
RSI (14)70.8Overbought
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · ABT · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$88.72BUY
MA 10$87.53BUY
MA 20$86.63BUY
MA 50$92.55SELL
MA 100$102.20SELL
MA 200$115.55SELL
Current $ABT · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$89.14BUY
EMA 10$88.19BUY
EMA 20$88.20BUY
EMA 50$92.82SELL
EMA 100$100.63SELL
EMA 200$109.62SELL
Current $ABT · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
BTIG2026-04-27
Maintains
BuyBuy
Barclays2026-04-20
Maintains
OverweightOverweight
B of A Securities2026-04-17
Maintains
BuyBuy
Oppenheimer2026-04-17
Maintains
OutperformOutperform
Piper Sandler2026-04-17
Maintains
OverweightOverweight
Benchmark2026-04-17
Maintains
BuyBuy
BTIG2026-04-17
Maintains
BuyBuy
RBC Capital2026-04-17
Maintains
OutperformOutperform
Evercore ISI Group2026-04-17
Maintains
OutperformOutperform
Stifel2026-04-17
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Abbott Laboratories (ABT) stock. Of the recent 437 rating actions, 22 were upgrades and 14 were downgrades. 41 analysts currently cover ABT.

Analyst Recommendation Trends

Buy ratings713↑ +6
Hold ratings00
Sell ratings00

ABT analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 7 to 13 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$50.4B

↓ 14.5% YoY

Revenue Next Year

$54.9B

↑ 9.0% YoY

EPS This Year

$5.47

EPS Next Year

$6.05

↑ 10.6% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast ABT EPS of $5.47 for the current fiscal year, based on estimates from 15 analysts. The ABT revenue forecast is $50.4B for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The ABT stock forecast is supported by two independent data sources: analyst consensus ratings from 41 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ABT price target is $127.46 (+40.0% upside), with an analyst consensus of Buy.

The ABT short-term stock prediction for tomorrow is $92.63 (+1.71%). The ABT stock price prediction for 2027 estimates an average of $89. The ABT stock prediction for 2030 projects a range of $83–$89.

Abbott Laboratories trades on NYSE under the ticker ABT. The ABT stock outlook for 2027 is broadly positive, supported by a Buy consensus among 76% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

ABT forecast · 8 questions

According to 41 Wall Street analysts, the average 12-month ABT price target is $127.46, with a high forecast of $152.00 and a low of $92.00. The median price target is shown in the chart above when available. This implies +40.0% potential upside from the current price of $91.07.

ABT price targetWhat is ABT price targetABT analyst price targetABT 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.